全文获取类型
收费全文 | 354669篇 |
免费 | 30302篇 |
国内免费 | 14215篇 |
专业分类
耳鼻咽喉 | 3762篇 |
儿科学 | 6276篇 |
妇产科学 | 3947篇 |
基础医学 | 59144篇 |
口腔科学 | 8367篇 |
临床医学 | 26806篇 |
内科学 | 56428篇 |
皮肤病学 | 6944篇 |
神经病学 | 23635篇 |
特种医学 | 7805篇 |
外国民族医学 | 155篇 |
外科学 | 27505篇 |
综合类 | 50108篇 |
现状与发展 | 65篇 |
一般理论 | 6篇 |
预防医学 | 14073篇 |
眼科学 | 5351篇 |
药学 | 43050篇 |
73篇 | |
中国医学 | 12587篇 |
肿瘤学 | 43099篇 |
出版年
2024年 | 837篇 |
2023年 | 6007篇 |
2022年 | 12175篇 |
2021年 | 15552篇 |
2020年 | 12515篇 |
2019年 | 11269篇 |
2018年 | 11201篇 |
2017年 | 11514篇 |
2016年 | 11891篇 |
2015年 | 13697篇 |
2014年 | 20619篇 |
2013年 | 22933篇 |
2012年 | 20000篇 |
2011年 | 22920篇 |
2010年 | 19074篇 |
2009年 | 18964篇 |
2008年 | 19038篇 |
2007年 | 18359篇 |
2006年 | 16531篇 |
2005年 | 14799篇 |
2004年 | 12773篇 |
2003年 | 11183篇 |
2002年 | 9035篇 |
2001年 | 7595篇 |
2000年 | 6361篇 |
1999年 | 5746篇 |
1998年 | 5355篇 |
1997年 | 4916篇 |
1996年 | 4394篇 |
1995年 | 3879篇 |
1994年 | 3477篇 |
1993年 | 2969篇 |
1992年 | 2443篇 |
1991年 | 2310篇 |
1990年 | 1849篇 |
1989年 | 1640篇 |
1988年 | 1560篇 |
1987年 | 1277篇 |
1986年 | 1180篇 |
1985年 | 1686篇 |
1984年 | 1556篇 |
1983年 | 1095篇 |
1982年 | 1136篇 |
1981年 | 901篇 |
1980年 | 775篇 |
1979年 | 608篇 |
1978年 | 407篇 |
1977年 | 330篇 |
1976年 | 286篇 |
1975年 | 161篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
BackgroundTo investigate perioperative complication rates at radical nephrectomy (RN) according to inferior vena cava thrombectomy (IVC-T) status and stage (metastatic vs non-metastatic) within kidney cancer patients.Materials and methodsWe ascertained perioperative complication rates within the National Inpatient Sample database (2016–2019). First, log-link linear Generalized Estimating Equation function (GEE) regression models (adjusted for hospital clustering and weighted for discharge disposition) tested complication rates in IVC-T patients, according to metastatic stage. Subsequently, a subgroup analysis relied on RN patients with or without IVC-T. Here, multivariable logistic regression models tested complication rates in RN patients according to IVC-T status, after propensity score matching including metastatic stage.ResultsOf 26,299 RN patients, 461 (2%) patients underwent IVC-T. Of those, 252 (55%) were non-metastatic vs 209 (45%) were metastatic. Rates of acute kidney injury (AKI), transfusion, cardiac, thromboembolic and other medical complications in non-metastatic vs metastatic patients were 40 vs 40%, 25 vs 22%, 21 vs 23%, 19 vs 14% and 38 vs 40%, respectively (all p ≥ 0.2). Metastatic stage in IVC-T patients did not predict differences in complications in log-link linear GEE regression models (all p > 0.1). However, in logistic regression models with propensity score matching, relying on the overall cohort of RN patients, IVC-T status was associated with higher complication rates (all p < 0.001): AKI (Odds ratio [OR]:2.60; 95%-CI [95%-Confidence interval: 1.97–3.44), transfusions (OR:2.40; 95%-CI: 1.72–3.36), cardiac (OR:2.27; 95%-CI: 1.49–3.47), thromboembolic (OR:9.07; 95%-CI: 5.21–16.58) and other medical complications (OR:2.01; 95%-CI: 1.52–2.66).ConclusionsThe current analyses indicate that presence of concomitant IVC-T is associated with higher complication rate at RN. Conversely, metastatic stage has no effect on recorded complication rates. 相似文献
2.
《Journal of infection and chemotherapy》2022,28(12):1639-1644
IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in Wuhan in December 2019, and has since caused a global pandemic. The efficacy of several drugs has been evaluated, and it is now evident that tocilizumab has a beneficial effect, especially combined with corticosteroids, in patients with Coronavirus Disease 2019 (COVID-19). However, the optimal timing of tocilizumab administration has not yet been established. The goal of the present study was to determine the optimal timing of tocilizumab administration after starting corticosteroid therapy in patients with COVID-19.MethodsWe retrospectively analyzed the clinical characteristics of patients who were hospitalized for COVID-19 and treated with tocilizumab and corticosteroids in our hospital. The patients were divided into concurrent and sequential groups. The concurrent group received tocilizumab ≤24 h after corticosteroids, and the sequential group received tocilizumab >24 h after corticosteroid administration.ResultsThe baseline clinical characteristics of tocilizumab administration were similar between the two groups. White blood cell counts were significantly lower and C-reactive protein levels were significantly higher in the concurrent group than the sequential group. In the concurrent group, tocilizumab administration led to a significant decrease in maximum body temperature. In addition, there were significantly more oxygen-free days in the concurrent group than in the sequential group. However, survival rate was not significantly different between the concurrent and the sequential groups.ConclusionsIn the combination therapy with tocilizumab and corticosteroids, early administration of tocilizumab after starting corticosteroid treatment is effective when treating COVID-19. 相似文献
3.
背景 致密性骨炎(OCI)和其他疾病有时难以鉴别,探讨血清骨转换生化标志物可为OCI的鉴别诊断提供依据。 目的 探索女性OCI患者的血清骨转换生化标志物的水平变化及临床意义。 方法 回顾性选取2013年6月至2022年2月在北京积水潭医院门诊及住院诊断为OCI的61例女性患者作为观察组,年龄15~50岁,平均(33.8±6.6)岁,病程2周~15年。选择同期61例女性体检健康者作为对照组,年龄15~48岁,平均(35.6±7.6)岁。比较两组一般临床资料和血清骨转换生化标志物水平,并对血清骨转换生化标志物与病情相关指标进行相关性分析。 结果 观察组血清白蛋白(45.4±2.9)g/L低于对照组(46.5±2.8)g/L(t=2.190,P<0.05)。血清骨转换生化标志物比较结果显示,观察组血清1型胶原羧基末端肽β特殊序列(β-CTX)〔0.28(0.23,0.37)μg/L〕、N-端骨钙素(OC)〔13.1(11.2,16.2)μg/L〕、25-羟维生素D3〔25-(OH)VD3〕〔(14.1±5.1)μg/L〕低于对照组〔0.36(0.29,0.48)μg/L,15.6(13.7,17.3)μg/L,(17.5±6.6)μg/L〕(Z=-2.983、-3.255,t=3.081,P<0.05)。长病程亚组OC水平〔14.6(12.4,18.5)μg/L〕高于短病程亚组〔11.7(10.2,14.0)μg/L〕(Z=-2.407,P<0.05)。多孕亚组β-CTX〔0.25(0.22,0.32)μg/L〕、OC水平〔12.2(10.3,15.0)μg/L〕低于非多孕亚组〔0.33(0.26,0.44)μg/L、13.4(12.0,18.8)μg/L〕(Z=-2.486、-1.897,P<0.05)。相关性分析显示,观察组血清1型前胶原氨基端延长肽(tP1NP)与妊娠次数、生产次数均呈负相关(rs=-0.276、-0.298,P<0.05),OC与体质指数(BMI)、视觉模拟评分法(VAS)评分、妊娠次数均呈负相关(rs=-0.284、-0.374、-0.360,P<0.05),25-(OH)VD3水平与BMI呈正相关(rs=0.275,P<0.05)。 结论 女性OCI患者血清OC、β-CTX水平明显降低,可为鉴别其他疾病提供依据;血清OC水平可以反映OCI患者的严重程度,同时OC水平与患者妊娠次数相关;tP1NP与妊娠次数、生产次数相关。 相似文献
4.
目的:探讨脑出血对酵母沉默信息调节因子2(Sirt2)和炎症的影响。方法:将胶原酶Ⅳ注入SD大鼠右侧
纹状体中建立脑出血模型,通过免疫印迹和ELISA 等方法测定大鼠脑出血后48 h 的Sirt2 的表达及炎症变化。利
用Hemin 诱导PC12 细胞损伤模拟体外脑出血模型,并检测Sirt2 及炎症变化;采用短发夹RNA(shRNA)-Sirt2 沉
默Sirt2 在PC12 细胞中的表达及对炎症的影响。结果:手术后48 h 脑出血行为学评分最低。脑出血组Sirt2 的表达
显著高于假手术组。脑出血组IL-6、IL-1β 表达显著升高。结论:脑出血可以促进Sirt2 的表达和炎症反应,降低
Sirt2 的表达可减缓炎症反应。
关键词 脑出血;沉默信息调节 相似文献
5.
6.
7.
8.
We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection. 相似文献
9.
10.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献